Currently, Neumora Therapeutics Inc [NMRA] is trading at $1.95, up 0.52%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NMRA shares have gain 1.56% over the last week, with a monthly amount drifted -21.37%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neumora Therapeutics Inc [NASDAQ: NMRA] stock has seen the most recent analyst activity on January 02, 2025, when RBC Capital Mkts downgraded its rating to a Sector Perform and also revised its price target to $4 from $29. Previously, JP Morgan downgraded its rating to Neutral on November 05, 2024, and dropped its price target to $15. On October 01, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $30 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $23 on July 22, 2024. Mizuho initiated its recommendation with a Outperform and recommended $20 as its price target on July 08, 2024. Deutsche Bank started tracking with a Hold rating for this stock on December 12, 2023, and assigned it a price target of $13. In a note dated October 10, 2023, William Blair initiated an Outperform rating and provided a target price of $26 on this stock.
This stock has fluctuated between a low of $1.81 and a high of $21.00 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Neumora Therapeutics Inc [NASDAQ: NMRA] shares were valued at $1.95 at the most recent close of the market. An investor can expect a potential return of 105.13% based on the average NMRA price forecast.
Analyzing the NMRA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.83, Equity is -0.74 and Total Capital is -0.98. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.9233 points at the first support level, and at 1.8967 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9833, and for the 2nd resistance point, it is at 2.0167.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Neumora Therapeutics Inc [NASDAQ:NMRA] is 10.98. As well, the Quick Ratio is 10.98, while the Cash Ratio is 8.69.
Transactions by insiders
Recent insider trading involved Fust Matthew K, Director, that happened on Oct 18 ’24 when 14049.0 shares were sold. Director, Fust Matthew K completed a deal on Oct 17 ’24 to sell 7739.0 shares. Meanwhile, Director Fust Matthew K bought 14049.0 shares on Oct 18 ’24.
